Table of Contents

- Lymphoma
- Multiple Myeloma
- Myeloid
**Lymphoma**

## NON-HODGKIN LYMPHOMA

### Poster Presentations

**Presentation #EP539:** Clinical Outcomes in Patients With Relapsed/Refractory Large B-Cell Lymphoma Receiving Third-Line Therapy: A Multicenter, Retrospective, Real-world Study in the United Kingdom  
**Lead Author and Presenter:** Christopher Fox, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom  
**Session:** Aggressive Non-Hodgkin lymphoma - Clinical

**Presentation #EP541:** OUTREACH: Preliminary Safety & Efficacy Results From a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) in the Non-university Setting  
**Lead Author and Presenter:** John Godwin, Providence Cancer Center, Earle A. Chiles Research Institute, Portland, OR, United States  
**Session:** Aggressive Non-Hodgkin lymphoma - Clinical

**Presentation #EP1165:** Systematic Literature Review (SLR) of the Efficacy and Safety of Second-Line (2L) Treatments for Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)  
**Lead Author and Presenter:** Fei Fei Liu, Bristol Myers Squibb, Princeton, NJ, United States  
**Session:** Quality of Life, Palliative Care, Ethics and Health Economics

**Presentation #EP1169:** Use of Chimeric Antigen Receptor T cell Therapies in Patients With Large B-Cell Lymphoma in the Real-World Setting: Systematic Literature Review  
**Lead Author and Presenter:** Fei Fei Liu, Bristol Myers Squibb, Princeton, NJ, United States  
**Session:** Quality of Life, Palliative Care, Ethics and Health Economics

## HODGKIN LYMPHOMA

### Poster Presentation

**Presentation #EP1178:** Targeted Landscape Review for Understanding Lymphoma Patient-Reported Outcome Assessment in the Era of Emerging Therapies  
**Lead Author and Presenter:** Stacie Hudgens, Regulatory and Access, Clinical Outcomes Solutions, Tucson, AZ, United States  
**Session:** Quality of Life, Palliative Care, Ethics and Health Economics
MULTIPLE MYELOMA

Oral Presentation

**Presentation #S187:** Iberdomide (IBER) in Combination With Dexamethasone (DEX) and Daratumumab (DARA), Bortezomib (BORT), or Carfilzomib (CFX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

**Lead Author and Presenter:** Sagar Lonial, Winship Cancer Institute, Emory University, Atlanta, GA, United States

**Session:** New Diagnostic and Therapeutic Approaches in Multiple Myeloma and AL Amyloidosis

**EHA Thematic Day Q&A:** June 14, 2021 4:00 PM-4:45 PM (CEST) Virtual Room 3

Poster Presentations

**Presentation #EP747:** Anakinra Prophylaxis in Patients With Relapsed/Refractory Multiple Myeloma Receiving Orvacabtagene Autoleucel (orva-cel)

**Lead Author and Presenter:** Luciano Costa, University of Alabama Birmingham, Birmingham, AL, United States

**Session:** Gene Therapy, Cellular Immunotherapy and Vaccination - Clinical

**Presentation #EP984:** Characteristics of Neurotoxicity Associated With Idecabtagene Vicleucel (Ide-cel, bb2121) in Patients With Relapsed and Refractory Multiple Myeloma in the Pivotal Phase 2 KarMMa Study

**Lead Author and Presenter:** Salomon Manier, Department of Hematologic Malignancies, Lille University Hospital, Lille, France

**Session:** Myeloma and Other Monoclonal Gammopathies - Clinical

**Presentation #EP988:** Pomalidomide, Bortezomib, and Dexamethasone After 1 Prior Line of Therapy in Relapsed or Refractory Multiple Myeloma: A Safety Subanalysis of the Phase 3 OPTIMISMM Trial

**Lead Author and Presenter:** Katja Weisel, Department of Oncology, Hematology, and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

**Session:** Myeloma and Other Monoclonal Gammopathies - Clinical
**Presentation #EP1009**: Idecabtagene Vicleucel (Ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in Patients With Relapsed and Refractory Multiple Myeloma: Updated KarMMa Results

**Lead Author and Presenter**: Albert Oriol, Institut Josep Carreras and Institut Catala d’Oncolgia, Hospital Germans Trias I Pujol, Badalona, Spain

**Session**: Myeloma and Other Monoclonal Gammopathies - Clinical

---

**Presentation #EP1013**: A Meta-analysis of Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed or Refractory Multiple Myeloma After Lenalidomide Exposure

**Lead Author and Presenter**: Faith E. Davies, NYU Grossman School of Medicine, Clinical Myeloma Program, Perlmutter Cancer Center, New York, NY, United States

**Session**: Myeloma and Other Monoclonal Gammopathies - Clinical

---

**Presentation #EP1019**: Pomalidomide, Dexamethasone, and Daratumumab in Relapsed Refractory Multiple Myeloma (MM-014 Phase 2 Trial): A Subanalysis of Patients Previously Treated With Lenalidomide and a Proteasome Inhibitor

**Lead Author and Presenter**: Nizar J. Bahlis, Tom Baker Cancer Centre, Calgary, Canada

**Session**: Myeloma and Other Monoclonal Gammopathies - Clinical

---

**Publication Only**

**Publication #PB1673**: Real-World Treatment Patterns in Clinical Outcomes in Patients With Multiple Myeloma in Different Geographical Regions: Findings From a Systematic Literature Review

**Lead Author**: Elena Zamangi, University of Bologna, Bologna, Italy
**Myeloid**

<table>
<thead>
<tr>
<th><strong>β-THALASSEMIA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Presentation</strong></td>
</tr>
<tr>
<td><strong>Presentation #S101:</strong> The BEYOND Study: Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Luspatercept in Adult Patients With Non-transfusion Dependent Beta-Thalassemia</td>
</tr>
<tr>
<td><strong>Lead Author and Presenter:</strong> Ali T. Taher, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon</td>
</tr>
<tr>
<td><strong>Session:</strong> Presidential Symposium; June 11, 2021 4:15 PM-4:30 PM (CEST) Virtual Room 1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Poster Presentations</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Presentation #EP1304:</strong> Fewer Red Blood Cell Transfusion Units and Visits Across Baseline Transfusion Burden Levels in Patients With Beta-Thalassemia Treated With Luspatercept in the Phase 3 BELIEVE Trial</td>
</tr>
<tr>
<td><strong>Lead Author and Presenter:</strong> Ali T. Taher, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon</td>
</tr>
<tr>
<td><strong>Session:</strong> Thalassemias</td>
</tr>
</tbody>
</table>

| **Presentation #EP1305:** Long-Term Efficacy and Safety Outcomes in the Phase 2 Study of Luspatercept in β-thalassemia |
| **Lead Author and Presenter:** Antonio Piga, University of Turin, Turin, Italy |
| **Session:** Thalassemias |

| **Presentation #EP1306:** Benefit of Continuing Therapy With Luspatercept in Patients With Beta-Thalassemia Who Do Not Achieve ≥33% Reduction in Red Blood Cell (RBC) Transfusion Burden (TB) in Weeks 13-24 in the BELIEVE Trial |
| **Lead Author and Presenter:** Antonio Piga, University of Turin, Turin, Italy |
| **Session:** Thalassemias |

| **Presentation #EP1315:** Quantifying the Healthcare Resource Use and Clinical Outcomes of Patients With Beta Thalassemia in England |
| **Lead Author and Presenter:** James Farrell, Bristol Myers Squibb, Princeton, NJ, United States |
| **Session:** Thalassemias |
# MYELODYSPLASTIC SYNDROME

## Poster Presentations

**Presentation #EP915**: Benefit of Continuing Luspatercept Therapy in Patients With Lower-Risk Myelodysplastic Syndromes Who Did Not Achieve Red Blood Cell Transfusion Independence by Week 25 in the MEDALIST Study  
**Lead Author and Presenter**: Ulrich Germing, University Hospital of Düsseldorf, Düsseldorf, Germany  
**Session**: Myelodysplastic Syndromes - Clinical

**Presentation #EP920**: Luspatercept Reduces Red Blood Cell Transfusions in Patients With Lower-Risk Myelodysplastic Syndromes Regardless of Baseline Transfusion Burden in the MEDALIST Study  
**Lead Author and Presenter**: Guillermo Garcia-Manero, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States  
**Session**: Myelodysplastic Syndromes - Clinical

**Presentation #EP930**: Quantifying the Healthcare Resource Use and Clinical Outcomes of Patients With Myelodysplastic Syndrome With Ringed Sideroblasts in England  
**Lead Author and Presenter**: James Farrell, Bristol Myers Squibb, Princeton, NJ, United States  
**Session**: Myelodysplastic Syndromes - Clinical

**Presentation #EP1182**: Health-Related Quality of Life (HRQoL) in Patients (Pts) With Myelodysplastic Syndromes (MDS) in the CONNECT® Myeloid Disease Registry  
**Lead Author**: Dennis A. Revicki, Outcomes Research Consulting, Sarasota, FL, United States  
**Session**: Quality of Life, Palliative Care, Ethics and Health Economics

## Publication Only

**Publication #PB1619**: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to Lower-Risk MDS in ESA-Naive Patients Requiring RBC Transfusions (the COMMANDS trial)  
**Lead Author**: Matteo Della Porta, Cancer Center IRCCS Humanitas Research Hospital and Department of Biomedical Sciences, Humanitas University, Milan, Italy
ACUTE MYELOID LEUKEMIA

Oral Presentations

**Presentation #S131:** Survival Outcomes From the QUAZAR AML-001 Trial With Oral Azacitidine for Patients With Acute Myeloid Leukemia in Remission by Disease Subtype, Cytogenetic Risk, and NPM1 Mutation Status at Diagnosis

**Lead Author and Presenter:** Hartmut Döhner, Universitätsklinikum Ulm, Ulm, Germany

**Session:** AML Classification

**EHA Thematic Day Q&A:** June 17, 2021 7:45 PM-8:30 PM (CEST) Virtual Room 2

**Presentation #S311:** Estimated Hospitalization-Related Costs With Oral Azacitidine (Oral-AZA) vs Placebo (PBO) for Remission Maintenance in Patients With Acute Myeloid Leukemia (AML) in Spain and the United Kingdom (UK)

**Lead Author:** Christopher Pocock, Kemp and Canterbury Hospital, Canterbury, United Kingdom

**Presenter:** Esther Natalie Oliva, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy

**Session:** Patient’s Voice and Health Outcomes in Hematology

**EHA Thematic Day Q&A:** June 15, 2021 8:45 PM-9:30 PM (CEST) Virtual Room 1

Poster Presentations

**Presentation #EP428:** Prognostic Factors of Overall and Relapse-Free Survival for Patients With Acute Myeloid Leukemia (AML) in Remission: Multivariate Analyses From the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA)

**Lead Author and Presenter:** Gail Roboz, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, United States

**Session:** Acute Myeloid Leukemia - Clinical

**Presentation #EP445:** Hematologic Adverse Events and Management Strategies for Patients With Acute Myeloid Leukemia (AML) in First Remission Receiving Oral Azacitidine (Oral-AZA) in the Phase 3 QUAZAR AML-001 Trial

**Lead Author and Presenter:** Farhad Ravandi, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

**Session:** Acute Myeloid Leukemia - Clinical

**Presentation #EP446:** Comparative Efficacy of Oral Versus Injectable Azacitidine in Patients With AML in First Remission After Intensive Chemotherapy: An Indirect Treatment Comparison (Sub-Analysis Update)

**Lead Author and Presenter:** Clara Chen, Bristol Myers Squibb, Princeton, NJ, United States

**Session:** Acute Myeloid Leukemia - Clinical
**Presentation #EP457:** A Phase 3 Study of Enasidenib (ENA) Versus Conventional Care Regimens (CCR) in Older Patients With Late-Stage Mutant-IDH2 (MIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

**Lead Author and Presenter:** Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

**Session:** Acute Myeloid Leukemia - Clinical

---

**Presentation #EP465:** Updated Pharmacodynamic and Survival Outcomes From the AG221-AML-005 Trial of Enasidenib (ENA) Plus Azacitidine (AZA) in Patients With Mutant IDH2 Newly Diagnosed Acute Myeloid Leukemia (ND-AML)

**Lead Author and Presenter:** Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

**Session:** Acute Myeloid Leukemia - Clinical

---

**Publication Only**

**Publication #PB1395:** Systematic Literature Review of the Efficacy and Safety of Maintenance Therapies for Adults With Acute Myeloid Leukemia in Complete Remission Who Are Ineligible for Hematopoietic Stem Cell Transplant

**Lead Author:** Beatrice Suero, Eversana, Burlington, ON, Canada

**Publication #PB1398:** Patient Preferences for Maintenance Therapy of Acute Myeloid Leukemia: A Discrete Choice Experiment Subanalysis of Patients in Germany and Italy

**Lead Author:** Katelyn Cutts, Evidera, Bethesda, MD, United States

**Publication #PB1406:** European Guidelines and Real-World Evidence of Maintenance Treatments for Adults With Acute Myeloid Leukemia in First Complete Remission

**Lead Author:** Moez Ahmed, Eversana, Burlington, ON, Canada
# MYELOFIBROSIS

## Oral Presentation

**Presentation #S203:** Overall and Progression-Free Survival in Patients Treated With Fedratinib as First-Line Myelofibrosis (MF) Therapy and After Prior Ruxolitinib (RUX): Results From the JAKARTA and JAKARTA2 Trials  
**Lead Author and Presenter:** Claire Harrison, Guy’s and St. Thomas’ Hospital, London, United Kingdom  
**Session:** Therapies and Targets in MPN  
**EHA Thematic Day Q&A:** June 16, 2021 4:00 PM-4:45 PM (CEST) Virtual Room 2

## Poster Presentation

**Presentation #EP1062:** Fedratinib Demonstrates Limited Suppression of T- and Natural Killer- (NK) Cell Activity Ex Vivo Compared With Ruxolitinib at Clinically Relevant Doses  
**Lead Author and Presenter:** Aarif Ahsan, Bristol Myers Squibb, Princeton, NJ, United States  
**Session:** Myeloproliferative Neoplasms - Biology & Translational Research

## Publication Only

**Publication #PB1702:** Efficacy and Safety of Luspatercept Versus Placebo in Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis on JAK2 Inhibitor Therapy and Requiring RBC Transfusions (INDEPENDENCE trial)  
**Lead Author:** Ruben Mesa, Mays Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX, United States

# CHRONIC MYELOID LEUKEMIA

## Poster Presentation

**Presentation #EP677:** Effect of Comorbidities on Patient Responses With First-Line Dasatinib Versus Imatinib in Chronic Myeloid Leukemia in Chronic Phase: Exploratory Post Hoc Analysis of DASISION  
**Lead Author and Presenter:** Massimo Breccia, Sapienza University, Rome, Italy  
**Session:** Chronic Myeloid Leukemia - Clinical

© 2021 Bristol-Myers Squibb Company 6/21 NP-WWM-NA-0137  
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.